Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2021  |  Volume : 34  |  Issue : 1  |  Page : 13-17

Evaluation of avanafil in the treatment of erectile dysfunction

1 Department of Dermatology, Andrology and STIs, Faculty of Medicine, Menoufia University, Menoufia, Egyp
2 Dermatology, Andrology and STIs, General Hospital of Berket-Elsabea, Menoufia University, Menoufia, Egypt

Correspondence Address:
Sarah M.A. El-Soud
Shebin El-Kom, Menoufia
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/mmj.mmj_115_19

Rights and Permissions

Objective To evaluate the post-marketing efficacy of avanafil 100 mg, safety, and the probable adverse events in the treatment of Egyptian men with erectile dysfunction (ED). Background ED is one of the most common sexual disorders due to organic, psychogenic, or mixed etiologies. Its prevalence ranges from 6 to 64% increasing with age. Avanafil is a highly selective and potent second-generation phosphodiesterase 5 inhibitor. Patients and methods This was a double-blind, placebo-controlled, crossover study including 26 patients with mild to severe ED using the International Index of Erectile Function-Erectile Function. Patients received avanafil 100 mg or placebo for 6 weeks each, with a 2-week washout period in between. It was taken 30 min precoital on-demand twice weekly. Follow-up was at the end of the third and sixth week. Results Avanafil 100 mg significantly increased the mean IEEF-EF score when compared with the baseline (P < 0.001) and when compared with the placebo (P = 0.005), while placebo was not significant (P > 0.05). On use of avanafil 100 mg, 45% of patients became normal (no ED, score >25) by the end of the sixth week; 40% showed different grades of improvement; and 15% showed no improvement. The onset of action of avanafil was within 30 min in 85% of responders. The reported adverse events were nasal congestion, headache, facial flushing, tingling of hands and/or feet, heartburn, and diarrhea. Conclusion Avanafil 100 mg has a rapid onset of action, is efficient, and a tolerable drug for the treatment of ED.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded57    
    Comments [Add]    

Recommend this journal